Protara Therapeutics, Inc. TARA 深 沪
等待开盘 07-02 09:30:00 美东时间
4.04
+0.220
+5.76%
华盛通- 最 高4.045
- 今 开3.80
- 成交量 139.24万股
- 最 低 3.765
- 昨 收 3.82
- 总市值 2.27亿
- 52周最高 7.82
- 市盈率 静 --
- 换手率 2.48%
- 52周最低 2.97
- 委 比 -92.12%
- 总股本 5620.42万
- 历史最高 800.00
- 量 比 1.27
- 振 幅 7.33%
- 历史最低 1.04
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Protara Therapeutics Announces Key Medical Leadership Transition
Protara Therapeutics ( ($TARA) ) has issued an announcement. On June 26, 2026, ...
06-30 05:30
Protara Therapeutics Stockholders Approve Governance and Share Increases
Protara Therapeutics ( ($TARA) ) just unveiled an announcement. Protara Therape...
06-16 05:06
Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen
$100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated May 13, 2026, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.001
05-29 05:20
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.
05-15 23:36
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26
JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.
05-15 02:19
Protara Therapeutics Q1 EPS $(0.31) Beats $(0.37) Estimate
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.37) by 16.22 percent. This is a 6.9 percent decrease over losses of $(0.29) per share
05-13 20:07
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
Protara Therapeutics To Demonstrate Interim Data From Cohort A Of Its Current Phase 2 Open-Label ADVANCED-2 Study Of TARA-002 In Participants With BCG-Naïve Non-Muscle Invasive Bladder Cancer At American Urological Association 2026 Annual Meeting
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, interim data
04-28 04:10
